Even if it is just due to the benefits of weight loss, reducing the burden of AFib and other CV conditions with a single drug is hard to dismiss.
Garca-Vega D, Snchez-Lpez D, Rodrguez-Carnero G, Villar-Taibo R, Viuela JE, Lestegs-Soto A, et al
This article summarizes what researchers know so far about MASLD, MASH and the use of GLP-1 receptor agonists to treat these chronic liver conditions
Managing GLP-1 fatigue isn't about pushing harder
any direct effect of GLP-1 medications on thyroid regulation is still being studied
Anyone researching Akkermansia probiotics for metabolic wellness should understand this pathway first: Akkermansia does not replace GLP-1 activity, but it may help support the gut conditions that influence metabolic signaling, including mucosal integrity, SCFA production, inflammatory balance, and microbiome resilience